CLINICAL TRIALS PROFILE FOR LNP023
✉ Email this page to a colleague
Clinical Trials for LNP023
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT03373461 ↗ | Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation | Completed | Novartis Pharmaceuticals | Phase 2 | Efficacy and safety of LNP023 in IgAN patients |
| NCT03439839 ↗ | Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | Active, not recruiting | Novartis Pharmaceuticals | Phase 2 | The main purpose of this study is to evaluate the efficacy of LNP023 in patients with PNH, showing signs of active hemolysis despite treatment with SoC (defined as an antibody with anti C5 activity). |
| NCT03832114 ↗ | Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted | Completed | Novartis Pharmaceuticals | Phase 2 | The study is an open-label, two cohort non-randomized study evaluating the efficacy, safety, and pharmacokinetics of LNP023 in patients with C3G (Cohort A) and patients who have undergone kidney transplant and have C3G recurrence (Cohort B). |
| NCT03896152 ↗ | Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria | Active, not recruiting | Novartis Pharmaceuticals | Phase 2 | The main purpose of this study is to evaluate the efficacy of LNP023 in patients with PNH, showing signs of active hemolysis. |
| NCT03955445 ↗ | OL Extension Study of LNP023 in C3G | Recruiting | Novartis Pharmaceuticals | Phase 2 | This is an open-label extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy |
| NCT04154787 ↗ | Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy | Recruiting | Novartis Pharmaceuticals | Phase 2 | This is a randomized, open-label, two arm, parallel group, proof-of-concept, non-confirmatory study evaluating the efficacy and safety of LNP023 compared with rituximab in subjects with membranous nephropathy (MN) who are at high risk of disease progression defined on the basis of antibody anti-PLA2R titre and proteinuria. |
| NCT04557462 ↗ | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy | Recruiting | Novartis Pharmaceuticals | Phase 3 | The purpose of this study is to evaluate the long-term safety and tolerability, of open label iptacopan in primary IgA nephropathy participants who have completed either the CLNP023X2203 or CLNP023A2301 clinical trials. The open-label design of the current study is appropriate to provide study participants the opportunity to receive treatment with iptacopan until marketing authorizations are received and the drug product becomes commercially available while enabling collection of long-term safety and tolerability data for the investigational drug. Furthermore efficacy assessments conducted every 6 months will afford the opportunity to evaluate the clinical effects of iptacopan on long-term disease progression. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for LNP023
Condition Name
Clinical Trial Locations for LNP023
Trials by Country
Clinical Trial Progress for LNP023
Clinical Trial Phase
Clinical Trial Sponsors for LNP023
Sponsor Name
